Unoprostone
Clinical data | |
---|---|
Trade names | Rescula |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Topical (eye drops) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 14 min |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.227.145 |
Chemical and physical data | |
Formula | C22H38O5 |
Molar mass | 382.541 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]
It was approved by the Food and Drug Administration in 2000.[3]
In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]
In 2015, the drug was discontinued in the U.S.[citation needed]
References
- ^ Micromedex Detailed Consumer Information
- ^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
- ^ "Drug Approval Package". Food and Drug Administration.
- ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.
See what we do next...
OR
By submitting your email or phone number, you're giving mschf permission to send you email and/or recurring marketing texts. Data rates may apply. Text stop to cancel, help for help.
Success: You're subscribed now !